Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Pre-treatment with iberdomide and dex in Vk*MYC mouse model reshapes bone marrow T cell compartment, promotes infiltration of naive T cells, and generates 100% response rates and long survival in subjects with high tumor burden.”
Title: An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden
Authors: Erin W Meermeier, Kirsten Pfeffer, Caleb K Stein, Meaghen Sharik, Megan Tien Du, Yuliza Tafoya Alvarado, Chang-Xin Shi, Yuan Xiao Zhu, Peter Leif Bergsagel, Marta Chesi
You can read the Full Article on Blood.
You can find more posts featuring Robert Orlowski on OncoDaily.
